Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

about

The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy.

P2860

Q37601909-AE9FB74F-323F-4516-886C-CA4702BC5DED Q38977166-6CF11A73-40EC-44C5-923F-86593B2B0E6D Q55278388-9654F0F7-E58D-42DB-831B-D067B9B7AF50

P2860

Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

Item

http://www.wikidata.org/entity/Q41875502

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Isoniazid-induced polyneuropat ...... tratification with genotyping?

@en

type

Item

label

Isoniazid-induced polyneuropat ...... tratification with genotyping?

@en

prefLabel

Isoniazid-induced polyneuropat ...... tratification with genotyping?

@en

P1476

Isoniazid-induced polyneuropat ...... tratification with genotyping?

@en

P2093

Christian J Hartmann

http://www.w3.org/2001/XMLSchema#string

Daniela Steinberger

http://www.w3.org/2001/XMLSchema#string

Hans Peter Hartung

http://www.w3.org/2001/XMLSchema#string

Lidija Konta

http://www.w3.org/2001/XMLSchema#string

Mark Stettner

http://www.w3.org/2001/XMLSchema#string

Tatjana Pabst

http://www.w3.org/2001/XMLSchema#string

P2860

Peripheral neuropathy with ethambutol

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.

Effect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid.

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review.

Isoniazid: metabolic aspects and toxicological correlates.

Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review.

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.

P304

e00326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BRB3.326

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bernd C Kieseier

P577

2015-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277414356

http://www.w3.org/2001/XMLSchema#string

P698

26355945

http://www.w3.org/2001/XMLSchema#string

P932

4559012

http://www.w3.org/2001/XMLSchema#string

Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

about

P2860

P2860

Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932